Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)
NCT02575560
·
clinicaltrials.gov ↗
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
EGFR-TKI Resistant Mutation
Interventions
OTHER:
history data
Sponsor
Qingdao Central Hospital